The Pituitary Gland: Your Body's Peptide Command Center
Pituitary Hormones
8 hormones
The pituitary gland weighs just 500 mg but orchestrates the output of every major endocrine organ in the body.
Amar & Weiss, Neurosurgery Clinics of North America, 2003
Amar & Weiss, Neurosurgery Clinics of North America, 2003
View as imageA pea-sized organ buried behind your nose controls whether you grow, reproduce, lactate, respond to stress, or retain water. The pituitary gland produces at least eight peptide and glycoprotein hormones that regulate nearly every endocrine organ downstream. It weighs roughly 500 milligrams in adults and measures about 12 mm across, yet damage to it can shut down the thyroid, adrenal glands, and gonads simultaneously.[1] For a broader look at how this gland connects to the prolactin system, the ACTH-cortisol axis, and reproductive gonadotropins, those individual articles go deeper on each hormone.
Key Takeaways
- The anterior pituitary contains five specialized cell types that produce six distinct hormones, including growth hormone, prolactin, ACTH, FSH, LH, and TSH.[1]
- The posterior pituitary releases oxytocin and vasopressin, both nine-amino-acid peptides synthesized in the hypothalamus and transported down nerve axons.[1]
- Growth hormone secretion is pulsatile, regulated by GHRH, somatostatin, and a third pathway through the GH secretagogue receptor identified by Pong et al. in 1996.[2]
- Synthetic GH-releasing peptides like GHRP-2 and hexarelin stimulate not only GH but also prolactin, ACTH, and cortisol, revealing cross-talk between pituitary cell types (Arvat et al., 1997).[3]
- POMC, a single precursor peptide processed in the pituitary, generates ACTH, alpha-MSH, and beta-endorphin from the same molecule.[4]
- Pituitary disorders affect an estimated 1 in 1,000 people, making this small gland one of the most clinically consequential structures in endocrinology.[5]
Two Lobes, Two Embryonic Origins
The pituitary is not one organ. It is two structures fused together during embryonic development, each with a completely different origin and function.[1]
The anterior lobe (adenohypophysis) develops from Rathke's pouch, an upward fold of tissue from the embryonic mouth. It becomes the larger portion of the adult gland and contains five specialized cell types: somatotropes (growth hormone), lactotrophs (prolactin), corticotropes (ACTH), gonadotropes (FSH and LH), and thyrotropes (TSH). Each cell type produces its hormone independently, but all are regulated by releasing and inhibiting factors that arrive from the hypothalamus through a dedicated portal blood vessel system.[1]
The posterior lobe (neurohypophysis) develops from the infundibulum, a downward extension of the brain itself. It does not synthesize hormones. Instead, it stores and releases oxytocin and vasopressin (also called antidiuretic hormone), both of which are made by neurons in the hypothalamus and transported down their axons into the posterior pituitary for storage.[1]
A third region, the intermediate lobe, exists in many species but is rudimentary in adult humans. In other animals it produces melanocyte-stimulating hormone (MSH). In humans, POMC-derived peptides including alpha-MSH are processed primarily in the anterior lobe and arcuate nucleus of the hypothalamus instead.[4]
The Anterior Lobe: Six Hormones from Five Cell Types
Growth Hormone and the Somatotropes
Somatotropes make up roughly 50% of all anterior pituitary cells and produce growth hormone (GH), a 191-amino-acid peptide.[1] GH secretion is not constant. It comes in pulses, primarily during deep sleep, and the amplitude of those pulses declines with age.
Three systems regulate GH release. Growth hormone-releasing hormone (GHRH) from the hypothalamus stimulates it. Somatostatin inhibits it. And a third pathway, identified through the study of synthetic GH secretagogues, operates through a distinct G-protein-coupled receptor in the pituitary.[2] Smith et al. (1996) showed that the oral compound MK-0677 amplified pulsatile GH release by binding this receptor, synergizing with GHRH through a separate signal transduction pathway and functionally antagonizing somatostatin.[6]
Pong et al. (1996) formally characterized this receptor as a new G-protein-coupled receptor, showing that its binding affinity correlated tightly with GH-secretory activity across structurally diverse secretagogues. GHRH and somatostatin did not displace binding at this site, confirming it was a separate receptor entirely.[2] This receptor was later identified as the growth hormone secretagogue receptor (GHSR), the natural ligand of which turned out to be ghrelin, the stomach-derived hunger hormone.
Tannenbaum and Bowers (2001) mapped the interaction further. In rats, immunoneutralization of somatostatin reversed blunted GH responses to the secretagogue GHRP-6, while blocking GHRH virtually obliterated them. This demonstrated that GH secretagogues depend on intact GHRH signaling to work, rather than simply suppressing somatostatin.[7] The GH/IGF-1 axis article covers how GH signals downstream.
Muccioli et al. (1998) used radioiodinated hexarelin to show that GH secretagogue receptors exist not only in the pituitary but also in the hypothalamus, choroid plexus, cerebral cortex, hippocampus, and medulla oblongata, with no sex-related differences. The receptors had dissociation constants (Kd) of 1.5 nM in the hypothalamus and 2.1 nM in the pituitary.[8]
Prolactin and the Lactotrophs
Lactotrophs produce prolactin, the peptide hormone that drives milk production. Unlike other anterior pituitary hormones, prolactin is under tonic inhibition: the hypothalamus continuously releases dopamine, which suppresses prolactin secretion. Remove that dopamine signal (through a pituitary stalk lesion, for example), and prolactin levels rise rather than fall.[1]
Prolactin's role extends beyond lactation. It modulates immune function, influences reproductive behavior, and is elevated during stress. Arvat et al. (1997) found that synthetic GH-releasing peptides GHRP-2 and hexarelin both stimulated prolactin release in humans, though less potently than thyrotropin-releasing hormone (TRH). This cross-stimulation revealed that the GHSR pathway has effects beyond somatotropes, reaching lactotrophs as well.[3] The dedicated prolactin article covers this hormone in depth.
ACTH and the Corticotropes
Corticotropes produce adrenocorticotropic hormone (ACTH), a 39-amino-acid peptide cleaved from a much larger precursor called pro-opiomelanocortin (POMC). The same POMC molecule also yields alpha-MSH and beta-endorphin, depending on which enzymes process it.[4]
Kim et al. (1999) showed that POMC mRNA levels in both the arcuate nucleus and pituitary decrease in diabetic rats and normalize with insulin treatment, linking metabolic status directly to POMC processing in the pituitary.[4] ACTH travels through the blood to the adrenal cortex, where it triggers cortisol release. The entire loop, from hypothalamic CRH to pituitary ACTH to adrenal cortisol, is called the hypothalamic-pituitary-adrenal (HPA) axis. It is the body's primary stress response system.
Arvat et al. (1997) demonstrated that synthetic GH-releasing peptides also stimulated ACTH and cortisol in humans at levels comparable to those produced by corticotropin-releasing hormone (CRH). This cross-talk between the GHSR and ACTH release has implications for understanding how ACTH drives cortisol production.[3]
Gonadotropins: FSH and LH
Gonadotropes produce both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the same cell type. Both are glycoprotein hormones rather than simple peptides, consisting of an alpha subunit shared with TSH and a unique beta subunit. GnRH from the hypothalamus controls their release, and the pulse frequency of GnRH determines whether FSH or LH predominates.[1]
FSH drives ovarian follicle development in females and spermatogenesis in males. LH triggers ovulation and stimulates testosterone production. The FSH and LH article covers their reproductive roles in detail.
TSH and the Thyrotropes
Thyrotropes produce thyroid-stimulating hormone (TSH), which drives the thyroid gland to produce T3 and T4. TSH release is stimulated by thyrotropin-releasing hormone (TRH) from the hypothalamus and suppressed by circulating thyroid hormones through negative feedback.[1] TSH is a glycoprotein that shares its alpha subunit with FSH and LH, an evolutionary hint that these hormones diverged from a common ancestral peptide.
The Posterior Lobe: Oxytocin and Vasopressin
The posterior pituitary is fundamentally different from the anterior lobe. It is neural tissue, not glandular tissue. The hormones it releases, oxytocin and vasopressin, are both nine-amino-acid peptides that differ by only two amino acids. Despite their similar structures, they have distinct receptors and radically different functions.[1]
Oxytocin is synthesized in the paraventricular and supraoptic nuclei of the hypothalamus. It drives uterine contractions during labor, milk ejection during breastfeeding, and has been linked to social bonding, trust, and pair-bond formation in both animal and human research.
Vasopressin (antidiuretic hormone, ADH) is produced by the same hypothalamic nuclei. It acts on the kidneys to promote water reabsorption, concentrating urine and preventing dehydration. It also constricts blood vessels, raising blood pressure. The vasopressin article covers these mechanisms in detail.
Schafer and Martin (1994) demonstrated that the posterior pituitary also contains opioid peptides derived from all three opioid precursor families. Beta-endorphin from the anterior lobe is secreted into the circulation as a hormone. Dynorphin A(1-8) in the posterior lobe locally modulates oxytocin release, acting as a paracrine signal rather than a circulating hormone.[9] This illustrates a broader principle: the pituitary is not just a hormone factory. It contains local regulatory peptides that modulate its own output.
How the Hypothalamus Controls the Pituitary
The hypothalamus governs the anterior pituitary through a private circulatory system called the hypothalamic-hypophyseal portal system. Releasing and inhibiting hormones travel from the median eminence of the hypothalamus through portal veins directly to the anterior pituitary, bypassing the general circulation entirely.[1]
This portal system is the reason the anterior pituitary responds so precisely to hypothalamic signals. The concentrations of releasing hormones in the portal blood are far higher than anything measured in peripheral circulation. When the pituitary stalk is severed (by trauma, surgery, or tumor), this connection is lost. Most anterior pituitary hormones drop because their stimulatory signals disappear. Prolactin is the exception: it rises, because the dominant hypothalamic signal controlling prolactin is inhibitory (dopamine).[5]
The posterior pituitary uses a completely different mechanism. Oxytocin and vasopressin travel down nerve axons from the hypothalamus and are released directly from axon terminals in the posterior lobe in response to neural signals, not portal blood-borne releasing factors.[1]
Cross-Talk Between Pituitary Cell Types
The traditional textbook model treats each pituitary cell type as an independent system. Research from the 1990s complicated that picture.
Adams et al. (1996) showed that GH-releasing peptides GHRP-2 and GHRP-6 stimulated both phosphatidylinositol hydrolysis (their primary pathway) and cAMP production in human pituitary somatotropinomas that carried constitutively active Gs-protein mutations. In tumors without those mutations, GHRPs potentiated the cAMP response to GHRH and pituitary adenylate cyclase-activating polypeptide (PACAP). This was direct evidence of cross-talk between the phospholipase C and adenylyl cyclase signaling pathways within the same pituitary cells.[10]
Arvat et al. (1997) extended this observation in vivo. When they gave healthy humans GHRP-2 or hexarelin, both compounds stimulated not only GH but also prolactin, ACTH, and cortisol. The ACTH and cortisol responses were comparable in magnitude to those produced by CRH itself.[3] This means a single synthetic peptide targeting somatotropes also activated corticotropes and lactotrophs, suggesting either shared receptor expression across cell types or paracrine signaling within the gland.
What Goes Wrong: Pituitary Disorders
Pituitary tumors (adenomas) account for roughly 10-15% of all intracranial tumors and are the most common pituitary pathology. Most are benign but can cause disease through hormone overproduction or by compressing surrounding structures.[5]
Prolactinomas are the most common pituitary adenomas, causing elevated prolactin, menstrual irregularity, and galactorrhea. They typically respond to dopamine agonist drugs.
Growth hormone-secreting adenomas cause acromegaly in adults (enlarged hands, feet, and facial features) and gigantism in children. Somatostatin analogs like octreotide are a primary treatment.
ACTH-secreting adenomas cause Cushing's disease, characterized by weight gain, hypertension, diabetes, and muscle wasting from chronic cortisol excess.
Hypopituitarism occurs when the pituitary fails to produce one or more hormones, either from tumor compression, surgery, radiation, or autoimmune destruction. Because the pituitary controls so many downstream glands, loss of pituitary function can simultaneously affect the thyroid, adrenals, and gonads. Owolabi et al. (2024) noted that evaluation requires testing each hormonal axis individually, as deficiencies can be selective or complete.[5]
Why Peptide Researchers Study the Pituitary
The pituitary is where many therapeutic peptides exert their primary effects. CJC-1295 and sermorelin act on pituitary somatotropes through the GHRH receptor. GHRP-2, GHRP-6, and hexarelin act on the same cells through the GHSR. MK-677 is an oral GHSR agonist. Tesamorelin is an FDA-approved GHRH analog.
All of these compounds work because the pituitary has the receptors and cellular machinery to respond to them. Understanding pituitary anatomy, cell type distribution, and receptor expression patterns is foundational to understanding why these peptides have the effects they do, and why some have off-target effects on prolactin, ACTH, or cortisol.
The Bottom Line
The pituitary gland is a two-lobed structure that produces eight hormones governing growth, reproduction, stress, metabolism, and water balance. The anterior lobe contains five specialized cell types regulated by hypothalamic releasing and inhibiting factors through a portal blood system. The posterior lobe stores and releases oxytocin and vasopressin from hypothalamic nerve terminals. Research from the 1990s revealed significant cross-talk between pituitary cell types and signaling pathways, complicating the traditional model of independent hormonal axes. This cross-talk explains why synthetic GH-releasing peptides affect not only growth hormone but also prolactin, ACTH, and cortisol.